Bayer (BAYRY) Q3 earnings and revenue miss estimates, pharma solid
FROM THE WIRE · FINANCE.YAHOO.COM
Bayer AG BAYRY reported third-quarter 2026 core earnings of 11 cents per American Depositary Receipt ("ADR"), which missed the Zacks Consensus Estimate of 13 cents. Core earnings per share declined 36.7% year over year, as improved operating performance was offset by a weaker…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe earnings and revenue miss versus estimates may weigh on the stock, while pharma supports results.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Bayer reported core earnings of 11 cents per ADR, below the 13 cent estimate.
- 02Sales rose 4.1% to $11.57 billion, below the $11.70 billion estimate.
- 03The pharmaceuticals division showed strong growth, particularly Nubeqa and Kerendia.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets